ZURICH - NLS Pharmaceutics Ltd. (NASDAQ:NLSP), a Swiss biopharmaceutical company, announced today that it has been granted an extension by the Nasdaq Hearings Panel to meet the exchange's continued listing requirements.
The extension provides the company with a deadline until October 14, 2024, to satisfy the minimum bid price and stockholders' equity standards necessary for its common shares to remain listed on The Nasdaq Capital Market.
The Nasdaq Listing Rule 5550(a)(2) necessitates a minimum bid price of $1.00 for the company's common shares, while Rule 5550(b)(1) requires a minimum of $2,500,000 in stockholders' equity. NLS must meet specific financial conditions by September 3, 2024, and additional requirements by the final October deadline.
NLS had previously been notified by Nasdaq on April 17, 2024, of its non-compliance with the minimum bid price requirement, and on May 22, 2024, for falling short of the stockholders' equity requirement. In response, the company requested a hearing, which took place on June 4, 2024, where it presented its plan to regain compliance.
Despite the extension, NLS acknowledges that there is no guarantee it will be able to meet the compliance deadlines or maintain its listing on The Nasdaq Capital Market.
Founded in 2015, NLS Pharmaceutics focuses on developing therapies for rare and complex central nervous system disorders. The company's management team is experienced in developing and commercializing product candidates.
This development is based on a press release statement and is presented without any assurance that NLS will achieve the necessary compliance within the given timeframe.
In other recent news, NLS Pharmaceutics has made significant strides in the development of innovative therapies for narcolepsy. The Swiss biopharmaceutical company announced a new patent application for a series of molecules targeting narcolepsy and other neurodegenerative conditions. This patent, filed by Aexon Labs, introduces non-sulfonamide dual orexin receptor agonists (DOXA) that have shown potential efficacy in sleep regulation and neuroprotection.
In another development, NLS Pharmaceutics reported significant findings from its preclinical study of mazindol, a drug shown to have a neuroprotective effect on nocturnal activity disrupted by orexin system damage. This discovery was presented at the American Society of Clinical Psychopharmacology, further solidifying the company's efforts in addressing sleep and wakefulness disorders.
However, the company has faced challenges with Nasdaq's stockholders' equity requirement, leading to a potential delisting of its securities. To counter this, NLS Pharmaceutics has scheduled a hearing with the Nasdaq Hearings Panel to appeal the delisting determination.
In a bid to raise funds, the company launched a registered direct offering and concurrent private placement of securities, with H.C. Wainwright & Co. serving as the exclusive placement agent. This move aims to generate an estimated $1.75 million, which will be directed towards working capital and general corporate purposes.
Furthermore, NLS Pharmaceutics has acquired a worldwide exclusive license from Aexon Labs, Inc. for a platform of dual orexin receptor agonists, potentially broadening its approach to treating neurological disorders.
InvestingPro Insights
As NLS Pharmaceutics Ltd. (NASDAQ:NLSP) navigates its way through the Nasdaq's regulatory landscape, investors are closely monitoring the company's financial metrics and market performance. According to recent data from InvestingPro, the company's market capitalization stands at a modest 7.16 million USD. This valuation reflects the challenges faced by the company, as evidenced by the significant 82.51% year-over-year decline in its price total return.
InvestingPro Tips highlight that NLSP's stock price has experienced considerable volatility, often moving in the opposite direction of the market. This trend may be a concern for investors looking for stability, especially considering that the stock has plummeted by 69.77% year-to-date. Additionally, the company does not pay dividends, which might deter income-focused investors.
From a financial standpoint, NLS Pharmaceutics has been grappling with profitability issues, as it has not been profitable over the last twelve months. The firm's operating income, adjusted for the last twelve months as of Q4 2023, was a negative 11.81 million USD, further underscoring the financial hurdles it faces.
For those considering an investment in NLS Pharmaceutics, or for current shareholders seeking to make informed decisions, InvestingPro provides a comprehensive suite of additional tips. There are currently 9 more InvestingPro Tips available for NLSP at InvestingPro. By using the coupon code PRONEWS24, new subscribers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, offering valuable insights that could help navigate the company's future in the biopharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.